-- Robert Preidt
FRIDAY, Nov. 18 (HealthDay News) -- Women who develop breast
tenderness after starting combination estrogen and progestin
menopause therapy have a 33 percent higher risk of developing
breast cancer than those who don't experience breast tenderness, a
new study says.
It also found that new-onset breast tenderness was not
associated with increased breast cancer risk among women taking
The findings, based on an analysis of data from more than 16,600
women on the combination therapy and nearly 10,750 taking estrogen
alone, appear in the Nov. 17 online edition of the journal
Breast Cancer Research and Treatment.
"This study showed that developing new breast tenderness after the start of hormone therapy was associated with increased breast cancer risk only in women on the combination estrogen plus progestin therapy, not estrogen therapy alone," study first author Dr. Carolyn Crandall, a professor of general internal medicine and a scientist with the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, said in a UCLA news release.
However, the association between breast tenderness and increased
cancer risk does not mean that there is a cause-and-effect
A study published last month by Crandall found that new-onset
breast tenderness was much more pronounced in women receiving the
combination therapy than in those receiving estrogen alone. The
association between new-onset breast tenderness and breast-density
changes was also more pronounced in women receiving the combination
"The consistent theme we've run across throughout these studies is that estrogen and progestin compared to estrogen alone have a more marked effect on breast tissue," Crandall said. "One theory is that there may be more growth of breast tissue, making the breasts more dense, when women take the combination therapy."
Higher breast density is linked with a higher risk of breast
Crandall stressed that women taking hormone therapy have only a
slight risk of developing breast cancer overall.
"We don't want to incite panic, because breast cancer is rare in women taking hormone therapy, but the point is that women are terrified of getting breast cancer as a result of menopausal hormone therapy," Crandall said.
"Where I think this (new) study would be important is for women already on either combination hormone therapy or estrogen alone," Crandall added. "If they do develop breast tenderness, it would be good for them to know the results of this study and to consider discussing them with their physician."
Women on hormone therapy who develop new-onset breast tenderness
should be sure to get their regular clinical breast exams and
mammograms, Crandall advised.
The U.S. National Institute of Child Health and Human
Development has more about
hormone replacement therapy.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.